Innate Pharma Partners with Sobi to Advance Lacutamab into Phase 3 for Rare T-Cell Lymphoma
Innate Pharma teams up with Sobi to launch TELLOMAK-3 Phase 3 trial of lacutamab for rare T-cell lymphoma, with $75M upfront and new CMO.
/ 3 items
#IPHA↓
FDA Clears Path for Key Phase 3 Trial of Lacutamab in CTCL Treatment
Innate Pharma is moving forward with the TELLOMAK 3 trial for lacutamab in advanced cutaneous T-cell lymphomas (CTCL), including Sézary syndrome (SS) and Mycosis fungoides (MF).
Innate Pharma Receives Strong Buy Recommendation for Cancer Drug Potential
Innate Pharma got a "Buy" rating & $8 target. Its cancer drug IPH4502 targets a huge $1.5 billion bladder cancer market.